// App-Quantinova.ai

: PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Researchers

Presenter

  • Pere Barba

Principal Investigators

  • Marta Ligero

  • Cecilia Carpio

  • Maria Balaguer

  • Víctor Navarro Garcés

  • Sabela Bobillo

  • Francisco Beas

  • Pau Abrisqueta

  • Roser Sala

  • Francesc Bosch

  • Gloria Iacoboni

  • Marc Simo

  • Raquel Perez-Lopez

Medical Centers

  • Department of Hematology, University Hospital Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron -, , Barcelona, Spain

  • Vall Hebron Institute of Oncology, Barcelona, Spain

  • Department of Nuclear Medicine. Vall D'Hebron University Hospital, Barcelona., Barcelona, ESP

  • Department of Hematology, University Hospital Vall d'Hebron, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Autonoma of Barcelona (UAB), BARCELONA, Spain

  • Department of Hematology, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain

  • Department of Hematology, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Locations

  • Spain

  • Venezuela

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • 18F-fluorodeoxyglucose

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Fludeoxyglucose (18F)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved